Market Overview

Why Viking Therapeutics Is Trading Higher Today

Share:

Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher on Friday.

BMO Capital initiated coverage on the stock with an Outperform rating and a price target of $14 per share.

Viking Therapeutics is a health care service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta.

Viking Therapeutics shares are trading up 3.23% at $7.36 on Friday. The stock has a 52-week range between $8.87 and $3.26.

Related Links:

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Moderna, Lonza Strike Deal To Manufacture Up To 1 Billion Doses Of Coronavirus Vaccine Candidate Annually

Latest Ratings for VKTX

DateFirmActionFromTo
Jun 2020BMO CapitalInitiates Coverage OnOutperform
May 2020Chardan CapitalInitiates Coverage OnBuy
May 2020B. Riley FBRMaintainsBuy

View More Analyst Ratings for VKTX
View the Latest Analyst Ratings

 

Related Articles (VKTX)

View Comments and Join the Discussion!

Posted-In: why it's movingPrice Target Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
GNMKCanaccord GenuityMaintains20.0
MCOUBSMaintains344.0
LIIUBSMaintains235.0
QDELPiper SandlerMaintains250.0
LOWBarclaysMaintains150.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com